Quest Diagnostics Inc vs Comfort Systems USA Inc — how do they compare? Quest Diagnostics Inc trades at $230.04 (market cap $25.48B), while Comfort Systems USA Inc trades at $1,727.02 (market cap $60.06B). The key difference: Comfort Systems USA Inc is far larger — about 2.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Comfort Systems USA Inc for 41 Days on average.
| DGX | FIX | |
|---|---|---|
Market Cap | $25.48B | $60.06B |
Volume | 941,866 | 371,896 |
Sector | Health | Industrials |
52-Week High | $247.45 | $2.07K |
52-Week Low | $173.49 | $790.72 |
Typical Hold Time | 56 Days | 41 Days |
Enterprise Value | $31.23B | $58.53B |
Dividend Yield | 1.49% | 0.21% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Comfort Systems USA (FIX) trades at $1,741.36, down 4.21% today but maintains strong technical momentum with bullish moving averages and support at $1,712. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $12.53 vs. $10.45, while revenue growth accelerates from $9.1B in 2025 to $11.2B in 2026. Recent acquisition of Hunt Electric adds $250M in annual revenue, positioning FIX to capitalize on data center and infrastructure demand.
FIX presents a compelling growth opportunity with 55.56% analyst buy ratings and a $2,080 consensus price target offering 19% upside. Key risks include execution challenges in integrating acquisitions and potential margin pressure from rising costs. The stock's premium valuation (P/E 42) requires sustained earnings growth, but strong ROE (55.29%) and expanding data center backlog support the bullish case.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →